{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T18:59:25Z","timestamp":1649185165427},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW - Fortschritte der Medizin"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s15006-020-0577-6","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T14:04:36Z","timestamp":1591625076000},"page":"60-63","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Grenzformen zwischen Typ-1- und Typ-2-Diabetes"],"prefix":"10.1007","volume":"162","author":[{"given":"Michael","family":"Hummel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"577_CR1","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2337\/dc12-0931","volume":"36","author":"MI Hawa","year":"2013","unstructured":"Hawa MI & Action LADA 7 Consortium. Adult-Onset Autoimmune Diabetes in Europe is Prevalent with a broad Clinical Phenotype. Diabetes Care 2013; 36: 908\u2013913","journal-title":"Diabetes Care"},{"key":"577_CR2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S0140-6736(97)03062-6","volume":"350","author":"R Turner","year":"1997","unstructured":"Turner R et al. Prospective Diabetes Study Group, UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes, Lancet 1997; 350: 1288\u20131293","journal-title":"Lancet"},{"key":"577_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","volume":"383","author":"T Tuomi","year":"2014","unstructured":"Tuomi T et al. The many faces of diabetes: A disease with increasing heterogeneity. Lancet 2014; 383: 1084\u201394","journal-title":"Lancet"},{"key":"577_CR4","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1007\/s00125-005-1960-7","volume":"48","author":"S Fourlanos","year":"2005","unstructured":"Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 2206\u201312","journal-title":"Diabetologia"},{"key":"577_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1530\/EJE-14-0342","volume":"71","author":"S Zampetti","year":"2014","unstructured":"Zampetti S, Campagna G, Tiberti C, et al. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). Eur J Endocrinol 2014; 71: 697\u2013704","journal-title":"Eur J Endocrinol"},{"key":"577_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6823-15-1","volume":"15","author":"M Hernandez","year":"2015","unstructured":"Hernandez M, Mollo A, Marsal JR, et al. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9. BMC Endocr Disord 2015; 15: 1","journal-title":"BMC Endocr Disord"},{"key":"577_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4093\/dmj.2018.0190","volume":"42","author":"S Pieralice","year":"2018","unstructured":"Pieralice S, Pozilli P. Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management. Diabetes Metab J 2018; 42: 451\u2013464","journal-title":"Diabetes Metab J"},{"key":"577_CR8","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1210\/jc.2007-2267","volume":"93","author":"T Maruyama","year":"2008","unstructured":"Maruyama T, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 2115\u201321","journal-title":"J Clin Endocrinol Metab"},{"key":"577_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.diabres.2008.09.044","volume":"83","author":"Z Yang","year":"2009","unstructured":"Yang Z, et al. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Research and Clinical Practice 2009; 83: 54\u201360","journal-title":"Diabetes Research and Clinical Practice"},{"key":"577_CR10","doi-asserted-by":"publisher","first-page":"E876","DOI":"10.1210\/jc.2013-3633","volume":"99","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains \u00df-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 2014; 99: E876\u201380","journal-title":"J Clin Endocrinol Metab"},{"key":"577_CR11","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.2337\/dc13-1523","volume":"37","author":"OE Johansen","year":"2014","unstructured":"Johansen OE, Boehm B, Grill V, et al. C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory results from a 2-year, double-blind, randomised, controlled study. Diabetes Care 2014; 37: e11\u2013e12","journal-title":"Diabetes Care"},{"key":"577_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.clim.2013.04.006","volume":"149","author":"J Pettus","year":"2013","unstructured":"Pettus J, Hirsch I, Edelman S. GLP-1 agonists in type 1 diabetes. Clin Immunol 2013; 149: 317\u201323","journal-title":"Clin Immunol"},{"key":"577_CR13","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/dom.13237","volume":"20","author":"P Pozzilli","year":"2018","unstructured":"Pozzilli P, Leslie RD, Peters AL, et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials. Diabetes Obes Metab 2018; 20: 1490\u20138","journal-title":"Diabetes Obes Metab"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-020-0577-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15006-020-0577-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-020-0577-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T23:24:02Z","timestamp":1623281042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-020-0577-6"}},"subtitle":["Seminar \/ Diabetes"],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["577"],"URL":"https:\/\/doi.org\/10.1007\/s15006-020-0577-6","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"10 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}